Drugs / BMS-936558-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04895709 | May 2021 → Aug 2031 expected | cervical cancer, colorectal cancer, gastroesophageal adenocarcinoma, head and neck squamous cell carcinoma +7 | Bristol-Myers Squibb | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-936558-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04895709 ↗ |